MUSTANG BIO, INC. Increase (Decrease) in Accounts Payable and Accrued Liabilities
MUSTANG BIO, INC. (MBIO) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$203.00 thousand for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2019-11-12
- MUSTANG BIO, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-09-30 was $76.00K, a 92.26% decline year-over-year.
- MUSTANG BIO, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-06-30 was -$1.31M, a 239.07% decline year-over-year.
- MUSTANG BIO, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2019-03-31 was $1.03M.
- MUSTANG BIO, INC. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2018-12-31 was $1.33M.
- MUSTANG BIO, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2018 was $2.47M, a 85.44% increase from fiscal 2017.
- MUSTANG BIO, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2017 was $1.33M, a 99.40% increase from fiscal 2016.
- MUSTANG BIO, INC. increase (decrease) in accounts payable and accrued liabilities for fiscal 2016 was $668.00K.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 7 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 10 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|---|
| 2019-09-30 | $76.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$1.23M derived: sum of 2 quarters · filed 2019-11-12 | -$203.00K 10-Q · filed 2019-11-12 | $1.13M derived: sum of 4 quarters · filed 2019-11-12 | ||
| 2019-06-30 | -$1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$279.00K 10-Q · filed 2019-08-09 | $1.05M derived: sum of 3 quarters · filed 2019-08-09 | $2.04M derived: sum of 4 quarters · filed 2019-11-12 | ||
| 2019-03-31 | $1.03M 10-Q · filed 2019-05-10 | $2.36M derived: sum of 2 quarters · filed 2019-05-10 | $3.35M derived: sum of 3 quarters · filed 2019-11-12 | $4.29M derived: sum of 4 quarters · filed 2019-11-12 | ||
| 2018-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $2.31M derived: sum of 2 quarters · filed 2019-11-12 | $3.26M derived: sum of 3 quarters · filed 2019-11-12 | $2.47M 10-K · filed 2019-03-18 | ||
| 2018-09-30 | $982.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $1.92M derived: sum of 2 quarters · filed 2019-11-12 | $1.14M 10-Q · filed 2019-11-12 | $546.00K derived: sum of 4 quarters · filed 2019-11-12 | ||
| 2018-06-30 | $942.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $155.00K 10-Q · filed 2019-08-09 | -$436.00K derived: sum of 3 quarters · filed 2019-08-09 | -$808.00K derived: sum of 4 quarters · filed 2019-08-09 | ||
| 2018-03-31 | -$787.00K 10-Q · filed 2019-05-10 | -$1.38M derived: sum of 2 quarters · filed 2019-05-10 | -$1.75M derived: sum of 3 quarters · filed 2019-05-10 | $662.00K derived: sum of 4 quarters · filed 2019-05-10 | ||
| 2017-12-31 | -$591.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | -$963.00K derived: sum of 2 quarters · filed 2019-03-18 | $1.45M derived: sum of 3 quarters · filed 2019-03-18 | $1.33M 10-K · filed 2019-03-18 | ||
| 2017-09-30 | -$372.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $2.04M derived: sum of 2 quarters · filed 2018-11-13 | $1.92M 10-Q · filed 2018-11-13 | $1.57M derived: sum of 4 quarters · filed 2018-11-13 | ||
| 2017-06-30 | $2.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $2.29M 10-Q · filed 2018-08-13 | $1.94M derived: sum of 3 quarters · filed 2018-08-13 | $2.65M derived: sum of 4 quarters · filed 2018-08-13 | ||
| 2017-03-31 | -$117.00K 10-Q · filed 2018-05-14 | -$474.00K derived: sum of 2 quarters · filed 2018-05-14 | $240.00K derived: sum of 3 quarters · filed 2018-05-14 | $435.00K derived: sum of 4 quarters · filed 2018-05-14 | ||
| 2016-12-31 | -$357.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $357.00K derived: sum of 2 quarters · filed 2018-03-29 | $552.00K derived: sum of 3 quarters · filed 2018-03-29 | $668.00K 10-K · filed 2018-03-29 | ||
| 2016-09-30 | $714.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $909.00K derived: sum of 2 quarters · filed 2017-11-14 | $1.02M 10-Q · filed 2017-11-14 | |||
| 2016-06-30 | $195.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $311.00K 10-Q · filed 2017-08-14 | ||||
| 2016-03-31 | $116.00K 10-Q · filed 2017-05-15 | |||||
| 2015-12-31 | $15.00K 10-K · filed 2018-03-29 | |||||
| 2015-09-30 | $17.00K 10-Q · filed 2016-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |